Opened the debate
White moved that the bill be read a second time, stating it would expand the vaccine definition to include emerging therapies. White argued this change was necessary to list products like Beyfortus, which protects infants from respiratory syncytial virus. White noted that the Pharmaceutical Benefits Advisory Committee had deferred recommending Beyfortus due to current legislative definitions. White claimed the bill would prevent fragmented access to healthcare and align with the National Immunisation Strategy for Australia 2025-2030.